O.I.P.E.
JUN 23 2003
PATENT & TRADEMARK OFFICE

RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on June 20, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____
Amelia Groth

Attorney Docket No. 407T-898010US
Client Ref. No. 2000-072-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#17
Plunkett
8/2/03

In re application of:	
Karen Reue, et al.	Examiner: Cynthia B. Wilder
Application No.: 10/028,056	Art Unit: 1637
Filed: December 19, 2001	
For: A NOVEL GENE ASSOCIATED WITH REGULATION OF ADIPOSITY AND INSULIN RESPONSE	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

OIPE JC156 JUN 23 2003 PATENT & TRADEMARK OFFICE

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

RECEIVED JUN 24 2003 TECH CENTER 1600/2900

Respectfully submitted,

Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

TH:ag

JUN 23 2003
PATENT & TRADEMARK

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	**10/028,056**
	Filing Date	**December 19, 2001**
	First Named Inventor	**Karen Reue**
	Group Art Unit	**1637**
(use as many sheets as necessary)	Examiner Name	**Cynthia B. Wilder**
	Attorney Docket Number	**407T-898010US**
	Date Submitted	June 20, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	01	5,476,926		Speigelman et al.	12-19-1995	
	02	5,698,389		de la Brousse et al.	12-16-1997	
	03	5,723,115		Serrero	03-03-1998	
	04	5,756,467		Kagawa et al.	05-26-1998	
	05	5,776,906		Sekiya	07-07-1998	
	06	5,827,740		Pittenger	10-27-1998	
	07	5,855,917		Cook et al.	01-05-1999	
	08	5,935,810		Freidman et al.	08-10-1999	

RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	09	WO	93/14109	A1	W. Alton Jones Cell Science Center	07-22-1993		
	10	WO	99/29725	A1	Merck & Co., Inc.	06-17-1999		
	11	WO	99/45135	A1	Millennium Biotherapeutics, Inc.	09-10-1999		
	12	WO	99/51740	A2	Janssen Pharmaceutica N.V.	10-14-1999		
	13	WO	00/28444	A1	Intel Corporation	05-18-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	14	**Ailhaud *et al.*** (1992) "Cellular and Molecular Aspects of Adipose Tissue Development" *Ann. Rev. Nutr.* 12: 207-233	
	15	**Cao and Hegele** (2000) "Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy" *Hum. Mol. Genet.* 9: 109-112	
	16	**Comuzzie *et al.*** (1997) "A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2" *Nature Genet.* 15: 273-275	
	17	**Dörfler *et al.*** (1993) "Lipoatrophic diabetes" *Clin. Investig.* 71: 264-269	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC156
JUN 23 2003
PATENT & TRADEMARK OFFICE

(Modified) PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**10/028,056**
Filing Date	**December 19, 2001**
First Named Inventor	**Karen Reue**
Group Art Unit	**1637**
Examiner Name	**Cynthia B. Wilder**
Attorney Docket Number	**407T-898010US**
Date Submitted	June 20, 2003

	18	**Garg** (2000) "Gender Differences in the Prevalence of Metabolic Complications in Familiarl Partial Lipodystrophy (Dunnigan Variety)" *J. Clin. Endocrinol. Metab.* 85: 1776-1782	
	19	**Hager *et al.*** (1998) "A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10" *Nature Genet.* 20: 304-308	
	20	**Klingenspor *et al.*** (1999) "Altered Gene Expression Pattern in the Fatty Liver Dystrophy Mouse Reveals Impaired Insulin-mediated Cytoskeleton Dynamics" *J. Biol. Chem.* 274: 23078-23084	
	21	**Langner *et al.*** (1989) "The Fatty Liver Dystophy (*fld*) Mutation" *J. Biol. Chem.* 264: 7994-8003	
	22	**Langner *et al.*** (1991) "Characterization of the Peripheral Neuropathy in Neonatal and Adult Mice That Are Homozygous for the Fatty Liver Dystophy (*fld*) Mutation" *J. Biol. Chem.* 266: 11955-11964	
	23	**Péterfy *et al.*** (1999) "Genetic, Physical, and Transcript Map of the *fld* Region on Mouse Chromosome 12" *Genomics* 62: 436-444	
	24	**Rehnmark *et al.*** (1998) "The fatty liver dystrophy mutant mouse: microvesicular steatosis associated with altered expression levels of peroxisome proliferator-regulated proteins" *J. Lipid Res.* 39: 2209-2217	
	25	**Rotimi *et al.*** (1999) "The Quantitative Trait Locus on Chromosome 2 for Serum Leptin Levels Is Confirmed in African-Americans" *Diabetes* 48: 643-644	
	26	**Seip and Trygstad** (1996) "Generalized lipodystrophy, congenital and acquired (lipoatrophy)" *Acta Paediatr. Scand. Suppl.* 413: 2-28	
	27	**Senior and Gellis** (1964) "The Syndromes of Total Lipodystrophy and of Partial Lipodystrophy" *Pediatrics* 33: 593-612	
	28	**Shackleton *et al.*** (2000) "*LMNA*, encoding lamin A/C, is mutated in partial lipodystophy" *Nature Genet.* 24: 153-156	
	29	**Shimomura *et al.*** (1998) "Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy" *Genes. Dev.* 12: 3182-3194	
	30	**Shimomura *et al.*** (1999) "Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and..." *Nature* 401: 73-76	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.